PHVS logo

PHARVARIS NV

PHVSNASDAQ
🏆 #1725 by market capEarnings Nov 18 · PostUS Equity
$32.83▲ $0.84 (+2.63%)
Pre-market · at close
🔔
Track PHVS
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 2.6%
7d▲ 7.0%
14d▲ 10.8%
30d▲ 3.5%
ytd▲ 18.3%
1y▲ 49.0%
🏦Market Cap
$2.30B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$31.75 – $32.86
52-Week Range
—
Volume (shares)
59,667
Avg Volume (shares)
—
Shares Outstanding
70.2M
Next Earnings
2026-11-18

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
—
Dividend Yield
—
Dilution (1yr)
+9.4%
PHVS logo

PHARVARIS NV

PHVS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$170M▲ +16.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$137M▲ +13.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
59.2M▲ +9.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$291M▲ +$11M YoY
StockOtter · stockotter.space

About PHARVARIS NV

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
21 analysts
Strong Buy9
Buy10
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.